Posted by Michael Wonder on 20 Sep 2022
CHMP adopts positive opinion for Mycapssa for the treatment of acromegaly
16 September 2022 - Positive opinion based on MPOWERED Phase 3 trial.
Amryt is pleased to announce that the EMA's CHMP has adopted a positive opinion, recommending the approval of Mycapssa in the European Union for the maintenance treatment of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide.
